Jury awards Centocor $1.7B in patent case against Abbott - St. Louis Business Journal:

http://vintageautorental.com/customerfeedback.html
An Abbott spokesman said the compantwill appeal. Horsham, Pa.-based Centocor, a division of makes the blockbuster rheumatoid arthritis treatment and had sued Abbottover Abbott’s arthrities drug, Humira. Both are so-called anti-TNF arthritis treatments. Pa.-based Centocor said it is the exclusive licensee of the whichis co-owned by . Centoco President Kim Taylor said “the jury recognized our valuableintellectuap property, finding our patent both valis and infringed. We will continue to assert intellectuak property rights for ourimmunology therapies, as they offefr significant advances in treatment for patients with a number of immund mediated inflammatory diseases.
” Abbott spokesman Scottg E. Stoffel said, “We are disappointeed in this verdict, and we are confident in the meritss of our case and that we will prevailon “The evidence clearly established that Humira was the first of its kind, fully-human anti-TNF antibody Stoffel said. “JNJ’s anti-TNF antibodgy medication, Remicade, is partially made from mousew DNA. JNJ did not launcyh a fully-human product until April 2009. In only when Humira was nearing its approva l in 2002 did JNJ amend the patent at issue in this litigatiojn to claim that it haddiscoveredx fully-human antibodies in 1994.
JNJ acknowledgeed at trial that it did not start working ona fully-huma n antibody until 1997 — two years after Abbott discovered Humira and one year aftet Abbott filed its patent applications for Humira.”